{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T16:41:58Z","timestamp":1769359318213,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>An aerosol foam formulation of fixed combination calcipotriol 50 \u03bcg\/g (Cal) and betamethasone 0.5 mg\/g (as dipropionate; BD) has been developed for psoriasis vulgaris treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare Cal\/BD aerosol foam pharmacodynamic activity with Cal\/BD ointment and with other topical corticosteroids of different potencies by assessing vasoconstrictor potential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Phase I, single\u2010centre, investigator\u2010blinded, vehicle\u2010controlled, intra\u2010individual comparison vasoconstriction study. Healthy volunteers received a single application on selected sites of: Cal\/BD aerosol foam, clobetasol propionate 0.5 mg\/g cream (CP; very potent), Cal\/BD ointment (potent), fluocinolone acetonide 0.25 mg\/g ointment (FA; moderately potent), BD aerosol foam and aerosol foam vehicle. A seventh untreated site acted as a negative control. Skin blanching was assessed by visual (primary response criterion) and colorimetric a* and L* measurements (secondary criteria), and was analysed over time (6\u201332 h post\u2010application).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010five healthy volunteers were included. All active treatments led to significantly greater skin blanching than control. By visual assessment, skin blanching with Cal\/BD aerosol foam was significantly less compared with CP cream [mean AUC<jats:sub>0\u201332<\/jats:sub> 2560 vs. 3831; mean difference = \u22121272; 95% confidence interval (CI): \u22121598, \u2212945; <jats:italic>P<\/jats:italic> &lt; 0.001], similar to BD aerosol foam (mean AUC<jats:sub>0\u201332<\/jats:sub> 2560 vs. 2595; mean difference = \u221235; 95% CI: \u2212362, 292; <jats:italic>P<\/jats:italic> = 0.83) and significantly greater than Cal\/BD ointment (mean AUC<jats:sub>0\u201332<\/jats:sub> 2560 vs. 2008; mean difference = 552; 95% CI: 225, 878; <jats:italic>P<\/jats:italic> = 0.001) and FA ointment (mean AUC<jats:sub>0\u201332<\/jats:sub> 2560 vs. 1981; mean difference = 578; 95% CI: 251, 905; <jats:italic>P<\/jats:italic> &lt; 0.001). Colorimetric assessments a* and L* also indicated significantly reduced skin blanching with Cal\/BD aerosol foam compared with CP cream. No adverse events (AEs) were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cal\/BD aerosol foam can be considered a more potent formulation than Cal\/BD ointment and the moderately potent FA ointment, but less potent than the very potent corticosteroid, CP cream.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13714","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T06:03:22Z","timestamp":1466057002000},"page":"1951-1956","source":"Crossref","is-referenced-by-count":23,"title":["Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments"],"prefix":"10.1111","volume":"30","author":[{"given":"C.","family":"Queille\u2010Roussel","sequence":"first","affiliation":[{"name":"Centre de Pharmacologie Clinique Appliqu\u00e9e \u00e0 la Dermatologie Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bang","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Clonier","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010P.","family":"Lacour","sequence":"additional","affiliation":[{"name":"Centre de Pharmacologie Clinique Appliqu\u00e9e \u00e0 la Dermatologie Nice France"},{"name":"Service de Dermatologie University Hospital of Nice Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6712"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.0948"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11207300-000000000-00000"},{"key":"e_1_2_6_7_1","article-title":"Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle","volume":"134","author":"Hollesen Basse L","year":"2014","journal-title":"J Invest Dermatol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1083935"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.844314"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D30W66C5GG","article-title":"A systematic review of adverse effects associated with topical treatments for psoriasis","volume":"9","author":"Bruner CR","year":"2003","journal-title":"Dermatol Online J"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630600845370"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1962.01590110044005"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1985.01660010067020"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04523.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.029"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000082572"},{"key":"e_1_2_6_17_1","first-page":"33","article-title":"Soleil et peau","volume":"2","author":"Fitzpatrick TB","year":"1975","journal-title":"J M\u00e9d Esth\u00e9t"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1991.tb00571.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00921.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.12.041"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1997.tb00267.x"},{"issue":"1","key":"e_1_2_6_22_1","first-page":"AB232","article-title":"Efficacy and safety of an innovative aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate in patients with psoriasis \u2013 the PSO\u2010FAST study","volume":"72","author":"Leonardi C","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"e_1_2_6_23_1","first-page":"AB222","article-title":"A novel aerosol foam formulation of calcipotriene (Cal) 0.005% plus betamethasone dipropionate (BD) 0.064% is more efficacious than Cal and BD foam alone in treating psoriasis vulgaris: a randomized, double\u2010blind, multicenter, three\u2010arm, Phase II study","volume":"72","author":"Lebwohl M","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"e_1_2_6_24_1","first-page":"PA","article-title":"Superior efficacy of the fixed combination calcipotriene plus betamethasone dipropionate in an innovative aerosol foam versus ointment, in patients with psoriasis vulgaris","volume":"34","author":"Koo J","year":"2015","journal-title":"Semin Cutan Med Surg"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948194"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07236.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323408"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13714","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:24:19Z","timestamp":1695572659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,15]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/jdv.13714"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13714","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,15]]}}}